The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 734,552 | - |
| Stock based compensation | - | 233,670 |
| Change in fair value of derivative liabilities | -201,360 | 192,613 |
| Net loss | - | -355,050 |
| Impairment of patent | 0 | 0 |
| Impairment of inventory | 0 | 0 |
| Amortization of license and patent | 0 | 0 |
| Amortization of debt discount | 0 | 0 |
| Management compensation | 338,670 | - |
| Depreciation | 1,500 | 1,000 |
| Gain on settlement of debt | 101,700 | - |
| Accounts receivable | 0 | 59 |
| Inventory | 4,654 | 20,459 |
| Prepaid expense | 0 | -100,000 |
| Accounts payable and accrued liabilities | 26,687 | 24,623 |
| Net cash used in operating activities | -151,309 | -208,888 |
| Purchase property and equipment's | 0 | 18,000 |
| Net cash used in investing activities | 0 | -18,000 |
| Proceeds from issuance of series d preferred stock | 0 | 300,000 |
| Proceeds from notes payable | 0 | 0 |
| Net cash provided by financing activities | 0 | 300,000 |
| Net change in cash | -151,309 | 73,112 |
| Cash and cash equivalents at beginning of period | 137,470 | - |
| Cash and cash equivalents at end of period | 59,273 | - |
BIOADAPTIVES, INC. (BDPT)
BIOADAPTIVES, INC. (BDPT)